Zhu Xue, Wang Ke, Zhang Kai, Zhang Ting, Yin Yongxiang, Xu Fei
Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
The Affiliated Maternity and Children Health Hospital of Nanjing Medical University, Wuxi 214002, China.
Int J Mol Sci. 2016 Nov 22;17(11):1903. doi: 10.3390/ijms17111903.
Due to the aggressive clinical behavior, poor outcome, and lack of effective specific targeted therapies, triple-negative breast cancer (TNBC) has currently been recognized as one of the most malignant types of tumors. In the present study, we investigated the cytotoxic effect of ziyuglycoside I, one of the major components extracted from Chinese anti-tumor herbal , on the TNBC cell line MDA-MB-231.
The underlying molecular mechanism of the cytotoxic effect ziyuglycoside I on MDA-MB-231 cells was investigated with cell viability assay, flow cytometric analysis and Western blot.
Compared to normal mammary gland Hs 578Bst cells, treatment of ziyuglycoside I resulted in a significant growth inhibitory effect on MDA-MB-231 cells. Ziyuglycoside I induced the G2/M phase arrest and apoptosis of MDA-MB-231 cells in a dose-dependent manner. These effects were found to be partially mediated through the up-regulation of p53 and p21, elevated Bax/Bcl-2 ratio, and the activation of both intrinsic (mitochondrial-initiated) and extrinsic (Fas/FasL-initiated) apoptotic pathways. Furthermore, the p53 specific siRNA attenuated these effects.
Our study suggested that ziyuglycoside I-triggered MDA-MB-231 cell cycle arrest and apoptosis were probably mediated by p53. This suggests that ziyuglycoside I might be a potential drug candidate for treating TNBC.
由于侵袭性的临床行为、较差的预后以及缺乏有效的特异性靶向治疗方法,三阴性乳腺癌(TNBC)目前已被公认为是最恶性的肿瘤类型之一。在本研究中,我们调查了从中国抗肿瘤草药中提取的主要成分之一紫玉兰糖苷I对TNBC细胞系MDA-MB-231的细胞毒性作用。
通过细胞活力测定、流式细胞术分析和蛋白质印迹法研究紫玉兰糖苷I对MDA-MB-231细胞产生细胞毒性作用的潜在分子机制。
与正常乳腺Hs 578Bst细胞相比,紫玉兰糖苷I处理对MDA-MB-231细胞产生了显著的生长抑制作用。紫玉兰糖苷I以剂量依赖性方式诱导MDA-MB-231细胞的G2/M期阻滞和凋亡。发现这些作用部分是通过p53和p21的上调、Bax/Bcl-2比值升高以及内在(线粒体启动)和外在(Fas/FasL启动)凋亡途径的激活介导的。此外,p53特异性小干扰RNA减弱了这些作用。
我们的研究表明,紫玉兰糖苷I引发的MDA-MB-231细胞周期阻滞和凋亡可能由p53介导。这表明紫玉兰糖苷I可能是治疗TNBC的潜在候选药物。